Cardio Diagnostics Engages Benefits Market to Tackle Cardiovascular Risk and Healthcare Costs

Cardiovascular disease remains one of the most expensive health conditions in the United States, accounting for approximately 11% of all U.S. healthcare expenditures in 2020–2021, according to the American Heart Association. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient's health, affecting employers, insurers, and healthcare systems through higher medical costs, lost productivity, and long-term care expenses. As organizations responsible for employee benefits seek new strategies to identify risk earlier and improve outcomes, Cardio Diagnostics Holdings (NASDAQ: CDIO) is engaging directly with these stakeholders at four national benefits conferences in June.

The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By participating in these conferences, Cardio Diagnostics plans to discuss innovative approaches to cardiovascular disease prevention, risk assessment, and cost management. The move comes as employers increasingly recognize the financial burden of cardiovascular disease and the potential for proactive health management to reduce overall healthcare spending.

Cardio Diagnostics' technology focuses on identifying individuals at elevated risk before symptoms appear, allowing for earlier lifestyle modifications or medical treatments. This proactive approach contrasts with traditional reactive models that often lead to costly emergency interventions. The company's solutions aim to help employers and insurers reduce the incidence of major cardiovascular events, thereby lowering direct medical costs and indirect costs related to lost productivity.

The conferences provide a platform for Cardio Diagnostics to network with benefits managers, insurance brokers, and corporate wellness directors who are key decision-makers in selecting health programs for employee populations. By demonstrating the potential return on investment through reduced healthcare claims and improved workforce health, the company hopes to expand adoption of its risk assessment tools.

For more information on Cardio Diagnostics and its latest developments, visit the company's newsroom at https://nnw.fm/CDIO.